• Explore /
  • Poster
  • / Randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high risk multiple myeloma (SWOG-1211).

Randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high risk multiple myeloma (SWOG-1211).

Abstract Poster

Authors

Saad Usmani

Saad Zafar Usmani

Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Saad Zafar Usmani , Antje Hoering , Sikander Ailawadhi , Rachael Sexton , Brea Lipe , Jason Neil Valent , Michael Alan Rosenzweig , Jeffrey A. Zonder , Madhav V. Dhodapkar , Natalie Scott Callander , Todd M. Zimmerman , Peter M. Voorhees , Brian G. Durie , S. Vincent Rajkumar , Paul G. Richardson , Robert Z. Orlowski

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT01668719

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 8054)

DOI

10.1200/JCO.2022.40.16_suppl.8054

Abstract #

8054

Poster Bd #

477

Abstract Disclosures

Similar Posters

First Author: Saad Zafar Usmani

First Author: Andrew Jenho Yee

First Author: O. Yellin

Poster

2023 ASCO Annual Meeting

Identification of genes encoding targets associated with adverse events in multiple myeloma.

Identification of genes encoding targets associated with adverse events in multiple myeloma.

First Author: Xuan Xu